

Kate M Lewis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/728189/publications.pdf>

Version: 2024-02-01

9
papers

135
citations

1162367
8
h-index

1473754
9
g-index

9
all docs

9
docs citations

9
times ranked

232
citing authors

#	ARTICLE	IF	CITATIONS
1	Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 1-12.	1.7	26
2	Blocking Neurogenic Inflammation for the Treatment of Acute Disorders of the Central Nervous System. <i>International Journal of Inflammation</i> , 2013, 2013, 1-16.	0.9	24
3	Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema Formation in an Experimental Model of Brain Tumors. <i>PLoS ONE</i> , 2014, 9, e97002.	1.1	21
4	Asymmetric cell division: Implications for glioma development and treatment. <i>Translational Neuroscience</i> , 2013, 4, 484-503.	0.7	14
5	NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 344-354.	0.7	14
6	Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours. <i>Cancer Cell International</i> , 2013, 13, 5.	1.8	13
7	Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface. <i>Recent Patents on CNS Drug Discovery</i> , 2011, 6, 31-40.	0.9	8
8	Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours. <i>Journal of Neuroimmunology</i> , 2012, 250, 59-65.	1.1	8
9	The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours. <i>Recent Patents on CNS Drug Discovery</i> , 2013, 8, 13-23.	0.9	7